CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); · Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry Aachen, Germany, 7 April 2021 / News Aktuell– Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk. In addition, Sustainalytics acknowledged that Grünenthal has a strong management of its ESG risks. This places Grünenthal in the top five percent of the global pharmaceuticals subsector.